C4 Therapeutics to Present at Upcoming Investor Conferences
Get Alerts CCCC Hot Sheet
Join SI Premium – FREE
WATERTOWN, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the following upcoming investor conferences:
- UBS Global Healthcare Conference on Wednesday, May 26, 2021 at 8:00 a.m. ET
- Jefferies Healthcare Conference on Tuesday, June 1, 2021 at 10:30 a.m. ET
A live webcast of each event can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. Replays of the webcasts will be archived on the C4T website for at least two weeks following the applicable presentation date.
About C4 TherapeuticsC4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.
Investor & Media Contact Kendra Adams SVP, Communications & Investor Relations [email protected]Source: C4 Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lerøy Seafood Group ASA: Primary Insider Transaction
- Granite Asia Ranked No. 1 Leading Financial Firm in Singapore for 2026, Metaclade Research Finds
- Battery X Metals Provides Board of Directors Update
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share